Drug intelligence / Profile preview

pseudoephedrine + chlorpheniramine + belladonna alkaloids

Development stage
Unknown
Lead developer
Yuhan
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination drug consisting of **pseudoephedrine**, **chlorpheniramine**, and **belladonna alkaloids**. - **Pseudoephedrine** is a sympathomimetic amine that acts as an alpha and beta adrenergic receptor agonist, leading to vasoconstriction and decongestion of nasal passages. - **Chlorpheniramine** is a first-generation antihistamine that acts as an antagonist at H1 histamine receptors, reducing the symptoms of allergies such as sneezing, itching, and runny nose. - **Belladonna alkaloids** are antimuscarinic agents (typically including atropine, hyoscyamine, and scopolamine) that produce anticholinergic effects such as reduction in glandular secretions, relaxation of smooth muscles, and antispasmodic actions. This combination is generally intended for symptomatic relief in upper respiratory conditions such as the **common cold**, **allergic rhinitis**, and related conditions where decongestion, antihistaminic, and antispasmodic effects are beneficial[2][3][5][7].

Other names
pseudoephedrine + chlorpheniramine + belladonna alkaloids
02

Targets

mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on pseudoephedrine + chlorpheniramine + belladonna alkaloids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pseudoephedrine + chlorpheniramine + belladonna alkaloids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call